Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vatalanib + Capecitabine in Advanced Cancer
NCT00171587Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2002
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vatalanib in cancer, solid tumor and colorectal cancer (CRC), sponsored by Novartis. Primary endpoints: Safety and Tolerability. Started May 2002; status: completed.
02
Drugs
vatalanib
03
Conditions
cancersolid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00171587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171587.